Actively Recruiting
Uppsala Psychosis Cohort
Led by Uppsala University · Updated on 2025-02-20
120
Participants Needed
1
Research Sites
456 weeks
Total Duration
On this page
Sponsors
U
Uppsala University
Lead Sponsor
U
Uppsala University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
A multimodal longitudinal study in early stage psychosis patients and individuals at high risk for psychosis. Healthy controls are included for baseline comparisons. The aim is to investigate disease mechanisms of psychotic disorders, specifically focusing on the synaptic pruning hypothesis.
CONDITIONS
Official Title
Uppsala Psychosis Cohort
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For early stage psychosis (EPP): diagnosis by DSM-5 of schizophrenia, schizophreniform psychosis, psychosis not otherwise specified, brief psychosis, schizoaffective syndrome, or delusional disorder
- Psychotic symptoms onset with functional decline within 3 years prior to inclusion
- For clinical high risk for psychosis (CHR-P): determined by Structured Interview for Psychosis-risk Syndromes (SIPS)
- Age between 18 and 40 years
- Ability to give informed consent and proficiency in Swedish language
You will not qualify if you...
- Other dominant psychiatric illness related to current psychotic symptoms (including bipolar disorder, major depressive disorder, autism)
- Long-term daily benzodiazepine treatment preventing testing participation
- History of major psychiatric disorder or substance use disorder for healthy controls
- Family history of psychotic or bipolar disorders in first degree relatives for healthy controls
- Significant somatic disorders or brain conditions (tumor, epilepsy, neuroinflammation, brain trauma)
- Effective radiation exposure over 25 mSv in past year
- Pregnancy, lactating, or breastfeeding
- Intellectual disability preventing informed consent
- Substance use disorder diagnosis or repeated positive urine screens during the study
- Metallic objects in the eye, electromagnetic implants, or claustrophobia related to MRI
- Severe infection symptoms within 7 days prior to inclusion
- Antihemostatic medication use within 2 weeks before lumbar puncture or arterial line placement
- Blood donation within 90 days, plasma donation within 1 week, or platelet donation within 6 weeks before inclusion
- Other investigator or sponsor determined reasons such as high symptom severity or hostility
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Uppsala University Hospital
Uppsala, Sweden
Actively Recruiting
Research Team
S
Simon Cervenka, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here